Sondel PM - Search Results

1

NK cell-based immunotherapies in Pediatric Oncology.

McDowell KA, Hank JA, DeSantes KB, Capitini CM, Otto M, Sondel PM. McDowell KA, et al. Among authors: sondel pm. J Pediatr Hematol Oncol. 2015 Mar;37(2):79-93. doi: 10.1097/MPH.0000000000000303. J Pediatr Hematol Oncol. 2015. PMID: 25590232 Free PMC article. Review.

2

Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression.

Bogner MP, Voss SD, Bechhofer R, Hank JA, Roper M, Poplack D, Hammond D, Sondel PM. Bogner MP, et al. Among authors: sondel pm. J Immunother (1991). 1992 Feb;11(2):111-8. J Immunother (1991). 1992. PMID: 1571333

3

Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2.

Albertini MR, Hank JA, Sondel PM. Albertini MR, et al. Among authors: sondel pm. Biotherapy. 1992;4(3):189-98. doi: 10.1007/BF02174205. Biotherapy. 1992. PMID: 1599802 Review. No abstract available.

4

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.

Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM. Weil-Hillman G, et al. Among authors: sondel pm. Cancer Res. 1990 May 1;50(9):2683-91. Cancer Res. 1990. PMID: 1691679

5

Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells.

Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM. Sosman JA, et al. Among authors: sondel pm. Blood. 1990 May 15;75(10):2005-16. Blood. 1990. PMID: 1692492 Free article.

6

Human T cell receptor-gamma delta-expressing T-cell lines recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-A, -B, -C, -DR, -DQ, or -DP.

Lam V, DeMars R, Chen BP, Hank JA, Kovats S, Fisch P, Sondel PM. Lam V, et al. Among authors: sondel pm. J Immunol. 1990 Jul 1;145(1):36-45. J Immunol. 1990. PMID: 1694208

7

Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein.

Rosenzweig IB, Wiebe DA, Hank JA, Albers JJ, Adolphson JL, Borden E, Shrago ES, Sondel PM. Rosenzweig IB, et al. Among authors: sondel pm. Biotherapy. 1990;2(3):193-8. doi: 10.1007/BF02173519. Biotherapy. 1990. PMID: 1698421 Clinical Trial.

8

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.

Voss SD, Robb RJ, Weil-Hillman G, Hank JA, Sugamura K, Tsudo M, Sondel PM. Voss SD, et al. Among authors: sondel pm. J Exp Med. 1990 Oct 1;172(4):1101-14. doi: 10.1084/jem.172.4.1101. J Exp Med. 1990. PMID: 1698909 Free PMC article.

9

In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients.

Gambacorti-Passerini C, Hank JA, Borchert A, Moore K, Malkovska V, Sondel P. Gambacorti-Passerini C, et al. Tumori. 1991 Oct 31;77(5):420-2. doi: 10.1177/030089169107700509. Tumori. 1991. PMID: 1781037

10

Immunological effects of levamisole in vitro.

Schiller JH, Lindstrom M, Witt PL, Hank JA, Mahvi D, Wagner RJ, Sondel P, Borden EC. Schiller JH, et al. J Immunother (1991). 1991 Oct;10(5):297-306. doi: 10.1097/00002371-199110000-00001. J Immunother (1991). 1991. PMID: 1790137

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

382 results

Search Page

Filters